ASH1L and breast cancer: Notably, we found that eight HMTs exhibited high-level amplification in more than 5% of breast cancers, and five of these eight HMTs (SMYD3, SETDB1, ASH1L, WHSC1L1, and SMYD2) had high-level amplification in more than 10% of samples.